The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...
The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S.
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...
The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...
The US Food and Drug Administration (FDA) has expanded the approval for Johnson & Johnson’s nasal spray Spravato to allow its ...
Ketamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.
The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder ...
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal ... the company said on Tuesday. The ketamine-derived drug was first approved in 2019 to be used in ...